Yayınlar & Eserler

Yayın Ağı
Makaleler 241
Tümü (241)
SCI-E, SSCI, AHCI (226)
SCI-E, SSCI, AHCI, ESCI (236)
ESCI (8)
Scopus (232)
TRDizin (19)
Diğer Yayınlar (6)

1. Effects of Intermittent Fasting on Liver Steatosis and Fibrosis, Serum FGF-21 and Autophagy Markers in Metabolic Dysfunction-Associated Fatty Liver Disease: A Randomized Controlled Trial

Karahan T. O., Akyuz E. Y., Karadag D. Y., Yilmaz Y., Eren F.
LIFE-BASEL , cilt.15, sa.5, ss.1-19, 2025 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

2. Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis

Eruzun H., Bossen L., Gökçe D. T., Ergenç İ., Harput Z. N., Aydemir N. G., et al.
Turkish Journal of Gastroenterology , cilt.36, sa.4, ss.241-246, 2025 (SCI-Expanded) identifier identifier

3. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

Anstee Q. M., Lucas K. J., Francque S., Abdelmalek M. F., Sanyal A. J., Ratziu V., et al.
Hepatology , cilt.78, sa.4, ss.1223-1239, 2023 (SCI-Expanded) identifier identifier

4. An international multidisciplinary consensus statement on MAFLD and the risk of CVD

Zhou X., Targher G., Byrne C. D., Somers V., Kim S. U., Chahal C. A. A., et al.
Hepatology International , cilt.17, sa.4, ss.773-791, 2023 (SCI-Expanded) Creative Commons License identifier identifier

5. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

Sun D., Targher G., Byrne C. D., Wheeler D. C., Wong V. W., Fan J., et al.
HEPATOBILIARY SURGERY AND NUTRITION , cilt.12, sa.3, 2023 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

6. TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.

Yılmaz Y., Zeybel M., Adalı G., Coşar A., Sertesen E., Sümer H., et al.
Hepatology forum , cilt.4, sa.Suppl 1, ss.1-32, 2023 (ESCI) Creative Commons License identifier identifier identifier

7. Real-world evidence on non-invasive tests and associated cut-offs used to assess fibrosis in routine clinical practice

Lazarus J. V., Castera L., Mark H. E., Allen A. M., Adams L. A., Anstee Q. M., et al.
JHEP Reports , cilt.5, sa.1, 2023 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

8. Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan

Yesil E. E., YILMAZ Y., Yesil A., Mese M., Kaya E., Bakir E. A.
HEPATOLOGY FORUM , cilt.4, sa.1, ss.14-18, 2023 (ESCI) Creative Commons License identifier identifier identifier identifier

9. Impairment of patient-reported outcomes among patients with non-alcoholic fatty liver disease: a registry-based study

YILMAZ Y., Toraman A. E., Alp C., Dogan Z., Keklikkiran C., Stepanova M., et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.57, sa.2, ss.215-223, 2023 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

10. The effects of dietary intervention on fibrosis and biochemical parameters in metabolic-associated fatty liver disease.

Ozlu T., Yilmaz Y., Gunes F. E.
Minerva gastroenterology , cilt.68, ss.426-433, 2022 (SCI-Expanded) identifier identifier

11. Severe impairment of patient-reported outcomes in patients with chronic hepatitis C virus infection seen in real-world practices across the world: Data from the global liver registry

Younossi Z. M., Yu M., El-Kassas M., Esmat G., Fernandez M. I. C., Buti M., et al.
JOURNAL OF VIRAL HEPATITIS , cilt.29, sa.11, ss.1015-1025, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

12. CLINICAL AND PATIENT-REPORTED OUTCOME (PRO) PROFILE OF PATIENTS WITH HEPATITIS B VIRAL (HBV) INFECTION FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))

Younossi Z. M., YILMAZ Y., Yu M., Alswat K. A., Buti M., Fernandez M. I. C., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

13. DEPRESSION AND EMOTIONAL DISTRESS IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (TM) (GLR (TM))

Younossi Z. M., Stepanova M., Fernandez M. I. C., YILMAZ Y., Yu M., El Kassas M., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded) identifier

14. REAL-WORLD EVIDENCE ON NON-INVASIVE TESTS AND ASSOCIATED CUT-OFFS USED TO ASSESS FIBROSIS IN ROUTINE CLINICAL PRACTICE

Lazarus J. V., Castera L., Mark H., Adams L. A., Allen A. M., Anstee Q. M., et al.
HEPATOLOGY , cilt.76, 2022 (SCI-Expanded) identifier

15. The impact of the COVID-19 pandemic on patients with chronic liver disease: Results from the Global Liver Registry

Younossi Z. M., Yilmaz Y., El-Kassas M., Duseja A., Hamid S., Esmat G., et al.
HEPATOLOGY COMMUNICATIONS , cilt.6, sa.10, ss.2860-2866, 2022 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

16. Clinical and Patient Reported Outcomes from Patients with Non-alcoholic Fatty Liver Disease Across the World: Data from the Global NASH/NAFLD Registry.

Younossi Z. M., Yilmaz Y., Yu M., Wai-Sun Wong V., Fernandez M. C., Isakov V. A., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association , cilt.20, sa.10, ss.2296, 2022 (SCI-Expanded) identifier identifier identifier

17. Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease

Younossi Z., Yilmaz Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

18. Multimodality assessment of hepatic fibrosis: ranked paired reading and artificial intelligence identifies fibrosis improvement with aramchol missed by conventional staging

Ratziu V., Yilmaz Y., Lazas D., Friedman S., Lackner C., Behling C., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded) identifier

19. Lean non-alcoholic fatty liver disease patients from the global NASH registry

Younossi Z., Yilmaz Y., Yu M., Wong V. W., Castellanos-Fernandez M., Isakov V., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded) identifier

20. Higher daily Aramchol dose results in higher effect size in fibrosis improvement in the ARMOR study open label part

Ratziu V., Yilmaz Y., Lazas D., Friedman S., Hayardeny L., Kadosh S., et al.
JOURNAL OF HEPATOLOGY , cilt.77, 2022 (SCI-Expanded) identifier

21. A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.

Younossi Z. M., Ong J. P., Takahashi H., Yilmaz Y., Eguchi Y., El Kassas M., et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association , cilt.20, 2022 (SCI-Expanded) identifier identifier identifier

22. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.

Mózes F. E., Lee J. A., Selvaraj E. A., Jayaswal A. N. A., Trauner M., Boursier J., et al.
Gut , cilt.71, ss.1006-1019, 2022 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

23. Global multi-stakeholder endorsement of the MAFLD definition.

Méndez-Sánchez N., Bugianesi E., Gish R. G., Lammert F., Tilg H., Nguyen M. H., et al.
The lancet. Gastroenterology & hepatology , cilt.7, sa.5, ss.388-390, 2022 (SCI-Expanded) identifier identifier identifier identifier

24. Insidious danger for young adults: Metabolic (dysfunction)associated fatty liver disease

Kaya E., YILMAZ Y.
HEPATOLOGY FORUM , cilt.3, sa.2, ss.39-40, 2022 (ESCI) Creative Commons License identifier identifier identifier identifier

25. Fibroscan detection of fatty liver and liver fibrosis in patients with systemic lupus erythematosus.

Yetginoglu O., Atas D., Yilmaz Y., Velioglu A., Arikan H., Alibaz-Oner F., et al.
Lupus , cilt.31, sa.6, ss.723-729, 2022 (SCI-Expanded) identifier identifier identifier

26. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?

Lazarus J. V., Mark H. E., Villota-Rivas M., Palayew A., Carrieri P., Colombo M., et al.
Journal of hepatology , cilt.76, ss.771-780, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

27. Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver

Kaya E., Yılmaz Y.
Journal of Clinical and Translational Hepatology , cilt.10, sa.2, ss.329-338, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

28. Advancing the global public health agenda for NAFLD: a consensus statement

Lazarus J., Mark H. E., Anstee Q. M., Arab J. P., Batterham R. L., Castera L., et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY , cilt.19, ss.60-78, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

29. Accuracy of Fibrosis-4 index and non-alcoholic fatty liver disease fibrosis scores in metabolic (dysfunction) associated fatty liver disease according to body mass index: failure in the prediction of advanced fibrosis in lean and morbidly obese individuals.

Eren F., Kaya E., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.34, ss.98-103, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

30. Prevention of hepatocellular carcinoma and surveillance of high risk patients

Kaya E., Mazzolini G. D., YILMAZ Y., CANBAY A.
Hepatology Forum , cilt.3, ss.33-38, 2022 (ESCI) Sürdürülebilir Kalkınma identifier identifier identifier identifier

31. Macro- and micronutrients in metabolic (dysfunction) associated fatty liver disease: association between advanced fibrosis and high dietary intake of cholesterol/saturated fatty acids.

Guveli H., Kenger E. B., Ozlu T., Kaya E., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.33, 2021 (SCI-Expanded) identifier identifier identifier

32. Demographic Characteristics and Transmission Risk Factors of Patients with Hepatitis C Virus in Turkey: The EPI-C, A Multicenter and Cross-sectional Trial

TABAK F., ŞİRİN G., DEMİR M., ALADAĞ M., SÜMER Ş., KURTARAN B., et al.
Viral Hepatitis Journal , cilt.27, sa.3, ss.109-117, 2021 (ESCI) Sürdürülebilir Kalkınma identifier identifier

33. A NOVEL STUDY DESIGN WITH ARAMCHOL EXPLORING THE KINETICS AND INTER-RELATIONS OF HISTOLOGICAL OUTCOME MEASURES AND NON-INVASIVE TESTS ASSOCIATED WITH NASH AND FIBROSIS FOR VARIABLE TREATMENT DURATIONS

Ratziu V., YILMAZ Y., Lazas D., De Guevara L. L., Kadosh S., Gorfine T., et al.
HEPATOLOGY , cilt.74, 2021 (SCI-Expanded) identifier

34. COVID-19 PANDEMIC AND CHRONIC LIVER DISEASE (CLD)

Younossi Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
HEPATOLOGY , cilt.74, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

35. FATIGUE AND NON-ALCOHOLIC FATTY LIVER DISEASE: DATA FROM THE GLOBAL NASH REGISTRY

Younossi Z. M., YILMAZ Y., Wong V. W., Fernandez M. I. C., Bugianesi E., Burra P., et al.
HEPATOLOGY , cilt.74, 2021 (SCI-Expanded) identifier

36. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study.

Wu X., Zheng K. I., Boursier J., Chan W., Yilmaz Y., Romero-Gómez M., et al.
EClinicalMedicine , cilt.41, ss.101145, 2021 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

37. Liver stiffness is associated with disease severity and worse clinical scenarios in coronavirus disease 2019: A prospective transient elastography study

Demirtas C. O., Keklikkiran C., Ergenc I., Erturk Sengel B., Eskidemir G., Cinel I., et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , cilt.75, sa.9, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

38. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease

KANİ H. T., DEMİRTAŞ C. Ö., KEKLİKKIRAN Ç., Ergenc I., Mehdiyev S., AKDENİZ E., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.8, ss.661-666, 2021 (SCI-Expanded) identifier identifier identifier identifier

39. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis

Mozes F., Lee J., Selvaraj E., Jayaswal A., Trauner M., Boursier J., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded) identifier

40. The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry

Younossi Z., YILMAZ Y., El-Kassas M., Duseja A. K., Hamid S. S., Esmat G., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

41. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement.

Hagström H., Adams L. A., Allen A. M., Byrne C. D., Chang Y., Grønbaek H., et al.
Hepatology (Baltimore, Md.) , cilt.74, ss.474-482, 2021 (SCI-Expanded) Creative Commons License identifier identifier identifier

42. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease

Younossi Z., Harrison S., Newsome P. N., Chan W., YILMAZ Y., de Ledinghen V., et al.
JOURNAL OF HEPATOLOGY , cilt.75, 2021 (SCI-Expanded) identifier

43. Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?

Demirtas C. O., Yilmaz Y.
Alimentary pharmacology & therapeutics , cilt.53, ss.1228-1229, 2021 (SCI-Expanded) identifier identifier identifier

44. Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic

AVCU A., Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.32, sa.5, ss.466-472, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

45. FIBROSCAN DETECTION OF FATTY LIVER AND LIVER FIBROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS

YETGİNOĞLU Ö., Atas D. B., VELİOĞLU A., ARIKAN İ. H., YILMAZ Y., ALİBAZ ÖNER F., et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION , cilt.36, ss.172, 2021 (SCI-Expanded) identifier

46. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study

YILMAZ Y., YILMAZ N., ATEŞ F., KARAKAYA F., GÖKCAN H., KAYA E., et al.
Hepatology Forum , cilt.2, sa.2, ss.37-42, 2021 (ESCI) identifier identifier

47. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.

Yilmaz Y., Byrne C., Musso G.
Expert review of gastroenterology & hepatology , cilt.15, ss.345-352, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

48. Recommendations for Reopening Endoscopy Units in Turkey: A Set-up Plan from a Tertiary Center in Istanbul.

Demirtas C. Ö., Keklikkıran Ç., Mehdiyev S., Ergenç İ., Özen Alahdab Y., Gündüz F., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.32, ss.113-115, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier identifier

49. High incidence of hepatitis B core antibody positivity in metabolic-associated fatty liver disease-related cirrhosis.

ERGENÇ İ., GÖKÇEN P., ADALI G., Kani H. T., Demirtaş C. Ö., Gündüz F., et al.
Hepatology forum , cilt.2, sa.1, ss.20-25, 2021 (Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

50. Comparison of aerobic and combined aerobic and whole-body vibration training effects on physical fitness in non-alcoholic fatty liver patients

Saldiran T. C., Mutluay F. K., Yagci İ., Yilmaz Y.
COMPARATIVE EXERCISE PHYSIOLOGY , cilt.17, sa.4, ss.393-401, 2021 (ESCI) identifier identifier

51. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

Razavi H., Blach S., Razavi-Shearer D., Polaris O.
Journal of viral hepatitis , cilt.28, ss.12-19, 2021 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

52. Letter: the use of Fibrosis-4 score in primary care and diabetology practices-Occam's razor applied to advanced fibrosis screening.

Yilmaz Y., Kaya E., Eren F.
Alimentary pharmacology & therapeutics , cilt.52, ss.1759-1760, 2020 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

53. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Eslam M., Sarin S., Wong V., Fan J., Kawaguchi T., Ahn S., et al.
HEPATOLOGY INTERNATIONAL , cilt.14, sa.6, ss.889-919, 2020 (SCI-Expanded) identifier identifier identifier

54. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients.

Hamurcu V., Kaya E., Alphan E., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.32, ss.1352-1357, 2020 (SCI-Expanded) identifier identifier identifier

55. Effect of carbon dioxide versus room air insufflation on post-colonoscopic pain: A prospective, randomized, controlled study.

Gündüz F., Kani H. T., Chang S., Akdeniz E., Eren F., Yılmaz Y., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.31, sa.10, ss.676-680, 2020 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier

56. Impact of aerobic training with and without whole-body vibration training on metabolic features and quality of life in non-alcoholic fatty liver disease patients.

Saldıran T., Mutluay F., Yağcı İ., Yılmaz Y.
Annales d'endocrinologie , cilt.81, ss.493-499, 2020 (SCI-Expanded) identifier identifier identifier

57. Metabolic-associated Fatty Liver Disease: Time to integrate ground-breaking new terminology to our clinical practice?

DEMİRTAŞ C. Ö., YILMAZ Y.
Hepatology Forum , cilt.1, sa.3, ss.79-81, 2020 (Hakemli Dergi) identifier

58. Regular coffee intake improves liver enzyme levels and liver histology in patients with chronic alcohol consumption, non-alcoholic fatty liver and non-alcoholic steatohepatitis: Report of 259 cases

DEĞERTEKİN M. B., TÖZÜN A. N., Söylemez A. G., Gurtay E., Bozkurt U., YILMAZ Y., et al.
Hepatology Forum , cilt.1, sa.3, ss.88-96, 2020 (Hakemli Dergi) identifier

59. Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD.

Sun D., Ye F., Kani H. T., Yang J., Zheng K., Zhang H., et al.
Diabetes & metabolism , cilt.46, sa.4, ss.288-295, 2020 (SCI-Expanded) identifier identifier identifier

60. The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance

DEMİRTAŞ C. Ö., SAPMAZ A., GÜREL B. A., KIZMAZ H., ULU T., KARAKETİR Ş. G., et al.
Hepatology Forum , cilt.1, sa.3, ss.101-108, 2020 (Hakemli Dergi) Sürdürülebilir Kalkınma identifier

61. Simple Noninvasive Scores Are Clinically Useful to Exclude, Not Predict, Advanced Fibrosis: A Study in Turkish Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease.

Kaya E., Bakir A., Kani H. T., Demirtas C., Keklikkiran C., Yilmaz Y.
Gut and liver , cilt.14, sa.4, ss.486-491, 2020 (SCI-Expanded) identifier identifier identifier

62. External validation of the Toronto hepatocellular carcinoma risk index in Turkish cirrhotic patients.

Demirtas C., Gunduz F., Kani H. T., Keklikkıran C., Alahdab Y., Yılmaz Y., et al.
European journal of gastroenterology & hepatology , cilt.32, sa.7, ss.882-888, 2020 (SCI-Expanded) identifier identifier identifier

63. A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

Eslam M., Newsome P., Anstee Q., Targher G., Gomez M., Zelber-Sagi S., et al.
Journal of hepatology , cilt.73, ss.202-209, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

64. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.

Alkayyali T., Qutranji L., Kaya E., Bakir A., Yilmaz Y.
Acta diabetologica , cilt.57, sa.5, ss.613-618, 2020 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

65. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.

Eslam M., Sanyal A., George J., International C.
Gastroenterology , cilt.158, 2020 (SCI-Expanded) identifier identifier identifier

66. The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease.

Enc F., Ulasoglu C., Bakir A., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.32, ss.597-600, 2020 (SCI-Expanded) identifier identifier identifier

67. The diagnostic utility of fibrosis-4 or nonalcoholic fatty liver disease fibrosis score combined with liver stiffness measurement by fibroscan in assessment of advanced liver fibrosis: a biopsy-proven nonalcoholic fatty liver disease study

Jafarov F., Kaya E., Bakir A., Eren F., Yilmaz Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.32, ss.642-649, 2020 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

68. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.

Newsome P., Sasso M., Deeks J., Paredes A., Boursier J., Chan W., et al.
The lancet. Gastroenterology & hepatology , cilt.5, ss.362-373, 2020 (SCI-Expanded) identifier identifier identifier identifier

69. Letter: the perilous road to a functional cure for hepatitis B infection.

Yilmaz Y.
Alimentary pharmacology & therapeutics , cilt.51, ss.577, 2020 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

70. Letter: a stepwise approach towards the screening of hepatic fibrosis in the general population.

Yilmaz Y.
Alimentary pharmacology & therapeutics , cilt.51, ss.669-670, 2020 (SCI-Expanded) Creative Commons License identifier identifier identifier

71. The comparison of resting metabolic rate betweenbiopsy-proven non-alcoholic steatohepatitis andnon-alcoholic fatty liver patients

KENGER E. B., GÜVELİ H., Ergun C., Kaya E., YILMAZ Y.
Hepatology Forum , cilt.1, sa.1, ss.14-19, 2020 (Hakemli Dergi) identifier

72. The utility of noninvasive scores in non-alcoholic fatty liver disease patients with normal and elevated serum transaminases

Kaya E., Bakır A., Eren F., Yılmaz Y.
Hepatology Forum , cilt.1, sa.1, ss.8-13, 2020 (Hakemli Dergi) Creative Commons License identifier

73. Arterial stiffness is associated independently with liver stiffness in biopsy-proven nonalcoholic fatty liver disease: a transient elastography study.

Bilgin B., Sunbul M., Kani H. T., Demirtas C., Keklikkiran C., Yilmaz Y.
European journal of gastroenterology & hepatology , cilt.32, ss.54-57, 2020 (SCI-Expanded) identifier identifier identifier

74. NFS Is Not a Marker of Nonalcoholic Fatty Liver Disease Per Se: What Is the True Relationship With CAD Complexity?

Yılmaz Y., Eren F.
ANGIOLOGY , cilt.71, ss.83-84, 2020 (SCI-Expanded) Creative Commons License identifier identifier identifier

75. Characterization of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease and Normal Aminotransferase Levels.

Ulasoglu C., Enc F., Kaya E., Yilmaz Y.
Journal of gastrointestinal and liver diseases : JGLD , cilt.28, ss.427-431, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

76. Transient elastography for assessing severe hepatic fibrosis in diabetic patients with nonalcoholic fatty liver disease: definitions matter

Yilmaz Y., Eren F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.31, sa.12, ss.1601-1602, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

77. Comments on "The Effect of Laparoscopic Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease"

Yılmaz Y., Eren F.
SURGICAL LAPAROSCOPY ENDOSCOPY & PERCUTANEOUS TECHNIQUES , cilt.29, sa.6, ss.548, 2019 (SCI-Expanded) identifier identifier identifier

78. Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., et al.
Revista da Associacao Medica Brasileira (1992) , cilt.65, ss.1470-1475, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

79. Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis

Hasturk B., Yilmaz Y., Eren F.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM , cilt.18, ss.463-475, 2019 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

80. Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease

Yilmaz Y., Eren F.
ATHEROSCLEROSIS , cilt.290, ss.222-223, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

81. Non-alcoholic fatty liver disease: A growing public health problem in Turkey

Kaya E., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.10, ss.865-871, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

82. Evaluation of depression, anxiety and quality of life in hepatitis C patients who treated with direct acting antiviral agents

Kesen O., Kani H. T., Yanartaş Ö., Aykut U., Gök B., Gündüz F., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.9, ss.801-806, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier identifier

83. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease

Younossi Z. M., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
Clinical Gastroenterology and Hepatology , cilt.17, ss.1625, 2019 (SCI-Expanded) identifier identifier identifier

84. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Younossi Z., Tacke F., Arrese M., Chander Sharma B., Mostafa I., Bugianesi E., et al.
Hepatology , cilt.69, ss.2672-2682, 2019 (SCI-Expanded) identifier identifier identifier

85. Liver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Dq S., Fang Zhoe Y., KANİ H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.
Journal Of Hepatology , cilt.70, ss.787, 2019 (SCI-Expanded) identifier

86. Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study

DEMİR M., Deyneli O., YILMAZ Y.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.30, sa.3, ss.266-270, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

87. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates

Younossi Z., Stepanova M., Ong J. P., Jacobson I. M., Bugianesi E., Duseja A., et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY , cilt.17, sa.4, ss.748-758, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

88. The optimal controlled attenuation parameter cut-offs in hepaticsteatosis grade differentiation by transient elastography(Fibroscan) in a sample of biopsy-proven non-alcoholic fatty liverdisease patients

Kaya E., BAKIR A., Sapmaz A. F., Kayyali T., Quatranji L., Çiftaslan A., et al.
Hepatology International , cilt.13, ss.196, 2019 (SCI-Expanded) identifier

89. Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter

Kani H. T., Deliktas I., YILMAZ Y.
MARMARA MEDICAL JOURNAL , cilt.32, sa.2, ss.68-70, 2019 (ESCI) identifier identifier

90. Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology

YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.31, sa.1, ss.43-46, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

91. Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience.

Yılmaz Y., Kani H. T., Demirtaş C., Kaya E., Sapmaz A., Qutranji L., et al.
The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology , cilt.30, ss.892-898, 2019 (SCI-Expanded) identifier identifier identifier

92. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality

Younossi Z., Maria S., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
Hepatology , cilt.68, ss.1, 2018 (SCI-Expanded)

93. THE SEQUENCE ANALYSIS OF NEW MITOCHONDRIALGENE, MOTS-C, IN PATIENTS WITH THE NON-ALCOHOLICSTEATOHEPATITIS

Önal O., Eren F., Yılmaz D., Göçmen T., Yılmaz Y.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL , cilt.6, ss.135, 2018 (SCI-Expanded)

94. Development of multiplex single base primer extension assay for the detection of potential association between MTNR1B gene polymorphisms and NASH

Yılmaz D., Eren F., Göçmen T., Yılmaz Y.
Journal Of Biotechnology , cilt.280, ss.76, 2018 (SCI-Expanded, Scopus) identifier

95. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease

Ozturk K., Dogan T., Celikkanat S., Ozen A., Demirci H., Kurt O., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.30, sa.4, ss.411-417, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

96. The correlation between histopathologic steatosis/fibrosis and various non-invasive imagingand blood fibrosis indicators of overweight and obese children

Tutar E., Şahin Akkelle B., Kesici C. B., Yılmaz Y., Çelikel Ç., Ergelen R., et al.
Journal Of Pediatric Gastroenterology And Nutrition , cilt.66, 2018 (SCI-Expanded)

97. Transient elastography with controlled attenuation parameter in the assessment of hepatic steatosis and significant liver fibrosis in patients with scleroderma

Yılmaz Y., Kani H. T., Şahinkaya Y., Deliktaş İ., Mursaloğlu H. H., Aziziy M., et al.
Hepatology International , cilt.12, 2018 (SCI-Expanded)

98. Recommendation for treatment of hepatitis C virus infection

KAYMAKOĞLU S., Koksal I., KAYMAKOĞLU S., Tabak F., Akarca U. S., Akbulut A., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

99. Nonalcoholic steatohepatitis and gut microbiota: Future perspectives on probiotics in metabolic liver diseases

YILMAZ Y., EREN F.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.28, sa.5, ss.327-328, 2017 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

100. The association of nonalcoholic fatty liver disease with genetic polymorphisms: A multicenter study

Uygun A., Ozturk K., Demirci H., Oztuna A., Eren F., Kozan S., et al.
European Journal of Gastroenterology and Hepatology , cilt.29, ss.441-447, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

101. Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter

Kaya E., Demir D., ÖZEN ALAHDAB Y., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.28, sa.11, ss.1264-1267, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

102. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis

ERGELEN R., YILMAZ Y., Asedov R., ÇELİKEL Ç., Akin H., BUĞDAYCI O., et al.
ABDOMINAL RADIOLOGY , cilt.41, sa.8, ss.1505-1510, 2016 (SCI-Expanded) identifier identifier identifier

103. The role of active brown adipose tissue in human metabolism

Ozguven S., Ones T., Yilmaz Y., Turoglu H. T., Imeryuz N.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.43, sa.2, ss.355-361, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

104. Diagnostic Role of Colon Capsule Endoscopy in Patients with Optimal Colon Cleaning

Akyüz Ü., Yılmaz Y., Ince A. T., Kaya B., Pata C.
Gastroenterology Research and Practice , cilt.2016, 2016 (SCI-Expanded) identifier identifier identifier

105. Is NAFLD different in absence of metabolic syndrome?

YILMAZ Y.
CLINICAL DILEMMAS IN NON-ALCOHOLIC FATTY LIVER DISEASE , ss.44-49, 2016 (SCI-Expanded) identifier

106. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease

Sünbül M., Kivrak T., Durmus E., Akin H., Aydin Y., Ergelen R., et al.
CARDIOVASCULAR THERAPEUTICS , cilt.33, ss.294-299, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

107. Diagnostic usefulness of FibroMeter VCTE for hepatic fibrosis in patients with nonalcoholic fatty liver disease

Dincses E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.10, ss.1149-1153, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

108. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease

Ozturk O., ÇOLAK Y., ŞENATEŞ E., YILMAZ Y., Ulasoglu C., Doganay L., et al.
WORLD JOURNAL OF GASTROENTEROLOGY , cilt.21, sa.26, ss.8096-8102, 2015 (SCI-Expanded) identifier identifier identifier

109. Measurements of serum procollagen-III peptide and M30 do not improve the diagnostic accuracy of transient elastography for the detection of hepatic fibrosis in patients with nonalcoholic fatty liver disease

ERGELEN R., Akyuz U., Aydin Y., EREN F., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.6, ss.667-671, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

110. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels

Akyuz U., Yesil A., YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.50, sa.3, ss.341-346, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

111. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease

Subasi C. F., Aykut U. E., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.27, sa.2, ss.137-141, 2015 (SCI-Expanded) identifier identifier identifier

112. No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects

Yonal O., EREN F., YILMAZ Y., ATUĞ Ö., Over H. H.
TURKISH JOURNAL OF GASTROENTEROLOGY , cilt.25, sa.6, ss.639-643, 2014 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier

113. Can Enhanced Autophagy Be Associated with Human Longevity? Serum Levels of the Autophagy Biomarker Beclin-1 Are Increased in Healthy Centenarians

Emanuele E., Minoretti P., Sanchis-Gomar F., Pareja-Galeano H., YILMAZ Y., Garatachea N., et al.
REJUVENATION RESEARCH , cilt.17, sa.6, ss.518-524, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

114. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness.

Sünbül M., Agirbasli M., Durmus E., Kivrak T., Akin H., Aydin Y., et al.
Atherosclerosis , cilt.237, sa.2, ss.490-3, 2014 (SCI-Expanded) identifier identifier identifier

115. A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease

YILMAZ Y., EREN F.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.26, sa.11, ss.1292-1295, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

116. A comparison of FibroMeter (TM) NAFLD Score, NAFLD fibrosis score, and transient elastography as noninvasive diagnostic tools for hepatic fibrosis in patients with biopsy-proven non-alcoholic fatty liver disease

Aykut U. E., Akyuz U., Yesil A., EREN F., Gerin F., ERGELEN R., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.11, ss.1343-1348, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

117. ARE PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE AT INCREASED RISK OF ASTHMA? - RESULTS FROM A TURKISH CROSS-SECTIONAL STUDY

Tasli B., YILMAZ Y.
RESPIROLOGY , cilt.19, ss.189, 2014 (SCI-Expanded) identifier

118. A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators

ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., ŞENATEŞ E., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES , cilt.23, sa.3, ss.311-319, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

119. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

Musso G., Gambino R., Tabibian J. H., Ekstedt M., Kechagias S., Hamaguchi M., et al.
PLOS MEDICINE , cilt.11, sa.7, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

120. Letter: gut microbiota modulation contributes to coffee's benefits for non-alcoholic fatty liver disease - authors' reply

Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.39, sa.12, ss.1442, 2014 (SCI-Expanded) identifier identifier identifier

121. Gallstone Disease Does Not Predict Liver Histology in Nonalcoholic Fatty Liver Disease

YILMAZ Y., Ayyildiz T., Akin H., ÇOLAK Y., Ozturk O., Senates E., et al.
GUT AND LIVER , cilt.8, sa.3, ss.313-317, 2014 (SCI-Expanded) identifier identifier identifier

122. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy

YILMAZ Y., Yesil A., Gerin F., ERGELEN R., Akin H., ÇELİKEL Ç., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.49, sa.5, ss.611-616, 2014 (SCI-Expanded) identifier identifier identifier

123. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease

YILMAZ Y., Senates E., Yesil A., ERGELEN R., ÇOLAK Y.
JOURNAL OF DIABETES AND ITS COMPLICATIONS , cilt.28, sa.3, ss.328-331, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

124. Obesity-Associated Nonalcoholic Fatty Liver Disease

YILMAZ Y., Younossi Z. M.
CLINICS IN LIVER DISEASE , cilt.18, sa.1, ss.19-32, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

125. Noninvasive detection of hepatic steatosis in patients without ultrasonographic evidence of fatty liver using the controlled attenuation parameter evaluated with transient elastography

YILMAZ Y., ERGELEN R., Akin H., Imeryuz N.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.25, sa.11, ss.1330-1334, 2013 (SCI-Expanded) identifier identifier identifier

126. Review article: coffee consumption, the metabolic syndrome and non-alcoholic fatty liver disease

Yesil A., Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.38, sa.9, ss.1038-1044, 2013 (SCI-Expanded) identifier identifier identifier

127. Biomarkers for Early Detection of Non-Alcoholic Steatohepatitis: Implications for Drug Development and Clinical Trials

YILMAZ Y.
CURRENT DRUG TARGETS , cilt.14, sa.11, ss.1357-1366, 2013 (SCI-Expanded) identifier identifier

128. Liver disease and malnutrition

Purnak T., YILMAZ Y.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY , cilt.27, sa.4, ss.619-629, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

129. Assessment of endothelial function in patients with nonalcoholic fatty liver disease

Colak Y., Senates E., Yesil A., YILMAZ Y., Ozturk O., Doganay L., et al.
ENDOCRINE , cilt.43, sa.1, ss.100-107, 2013 (SCI-Expanded) identifier identifier identifier

130. Letter: diagnostic accuracy of M30 levels for identifying patients with non-alcoholic steatohepatitis

Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.37, sa.2, ss.283, 2013 (SCI-Expanded) identifier identifier identifier

131. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back

YILMAZ Y., ÇOLAK Y., Kurt R., Senates E., EREN F.
TUMORI , cilt.99, sa.1, ss.10-16, 2013 (SCI-Expanded) identifier identifier identifier

132. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease

YILMAZ Y., Ozturk O., Alandab Y., Senates E., ÇOLAK Y., Doganay H. L., et al.
DIGESTIVE AND LIVER DISEASE , cilt.45, sa.1, ss.58-62, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

133. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis

YILMAZ Y., EREN F.
CLINICA CHIMICA ACTA , cilt.414, ss.154-157, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

134. Is nonalcoholic fatty liver disease the hepatic expression of the metabolic syndrome?

Yılmaz Y.
World Journal of Hepatology , cilt.4, ss.332-334, 2012 (SCI-Expanded) identifier identifier

135. Hepatic expression and serum levels of syndecan 1 (CD 138) in patients with nonalcoholic fatty liver disease

YILMAZ Y., EREN F., ÇOLAK Y., Senates E., ÇELİKEL Ç., Imeryuz N.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.47, sa.12, ss.1488-1493, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

136. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?

Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.36, sa.9, ss.815-823, 2012 (SCI-Expanded) identifier identifier identifier

137. Research update for articles published in EJCI in 2010

Adlbrecht C., Aigner E., Bellon J. M., Bouloukaki I., Bouzas-Mosquera A., Carrilho A. J. F., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.42, sa.11, ss.1149-1164, 2012 (SCI-Expanded) identifier identifier

138. Serum proteomics for biomarker discovery in nonalcoholic fatty liver disease

YILMAZ Y.
CLINICA CHIMICA ACTA , cilt.413, ss.1190-1193, 2012 (SCI-Expanded) identifier identifier identifier

139. Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk

Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.36, sa.4, ss.345-352, 2012 (SCI-Expanded) identifier identifier identifier

140. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease

Eren F., Kurt R., Ermis F., Atuğ Ö., Imeryuz N., Yılmaz Y.
Clinical Biochemistry , cilt.45, ss.655-658, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

141. Nonalcoholic Fatty Liver Disease: A Nutritional Approach

ÇOLAK Y., TUNCER İ., Senates E., Ozturk O., Doganay L., YILMAZ Y.
METABOLIC SYNDROME AND RELATED DISORDERS , cilt.10, sa.3, ss.161-166, 2012 (SCI-Expanded) identifier identifier identifier

142. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis

YILMAZ Y., Yonal O., Deyneli O., ÇELİKEL Ç., Kalayci C., DUMAN D.
ACTA GASTRO-ENTEROLOGICA BELGICA , cilt.75, sa.2, ss.240-244, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

143. Review article: fructose in non-alcoholic fatty liver disease

Yilmaz Y.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS , cilt.35, ss.1135-1144, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

144. Unconjugated hyperbilirubinemia and liver histology in patients with non-alcoholic fatty liver disease

Kurt R., YILMAZ Y.
CLINICAL BIOCHEMISTRY , cilt.45, sa.6, ss.515, 2012 (SCI-Expanded) identifier identifier identifier

145. Circulating vaspin and its relationship with insulin sensitivity, adiponectin and liver histology in subjects with non-alcoholic steatohepatitis

YILMAZ Y.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.47, sa.4, ss.489-490, 2012 (SCI-Expanded) identifier identifier identifier

146. Characterization of nonalcoholic fatty liver disease unrelated to the metabolic syndrome

YILMAZ Y., Senates E., Ayyildiz T., Colak Y., Tuncer I., Ovunc A. O. K., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.42, sa.4, ss.411-418, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

147. Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology

Colak Y., Senates E., Ozturk O., YILMAZ Y., Zemheri E., Enc F. Y., et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.24, sa.3, ss.255-261, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

148. Is M65 really better than M30 as a biomarker of hepatic fibrosis?

YILMAZ Y., Kurt R.
HEPATOLOGY , cilt.55, sa.2, ss.654, 2012 (SCI-Expanded) identifier identifier identifier

149. NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Factors for Disease Progression?

YILMAZ Y.
SEMINARS IN LIVER DISEASE , cilt.32, sa.1, ss.14-21, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

150. Preliminary evidence of an association between the functional c-kit rs6554199 polymorphism and achalasia in a Turkish population

Alahdab Y., Eren F., Giral A., Gunduz F., Kedrah A. E., Atug O., et al.
NEUROGASTROENTEROLOGY AND MOTILITY , cilt.24, sa.1, ss.27-30, 2012 (SCI-Expanded) identifier identifier identifier

151. The impact of early percutaneous endoscopic gastrostomy placement on treatment completeness and nutritional status in locally advanced head and neck cancer patients receiving chemoradiotherapy

Atasoy B. M., Yonal O., Demirel B., DANE F., YILMAZ Y., Kalayci C., et al.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , cilt.269, sa.1, ss.275-282, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

152. Concentrations of connective tissue growth factor in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

ÇOLAK Y., Senates E., Coskunpinar E., Oltulu Y. M., Zemheri E., Ozturk O., et al.
DISEASE MARKERS , cilt.33, sa.2, ss.77-83, 2012 (SCI-Expanded) identifier identifier identifier

153. A Glance at the methods for detection of apoptosis qualitatively and quantitatively Apoptozun nitel ve nicel olarak tespitine yönelik metotlara ki{dotless}sa bir baki{dotless}ş

Ulukaya E., Acilan C., Ari F., Ikitimur E., Yılmaz Y.
Turkish Journal of Biochemistry , cilt.36, ss.261-269, 2011 (SCI-Expanded) identifier

154. Serum osteocalcin levels in patients with nonalcoholic fatty liver disease: Association with ballooning degeneration

YILMAZ Y., Kurt R., EREN F., Imeryuz N.
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION , cilt.71, sa.8, ss.631-636, 2011 (SCI-Expanded) identifier identifier identifier

155. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis

YILMAZ Y., EREN F., Ayyildiz T., Colak Y., Kurt R., Senates E., et al.
CLINICA CHIMICA ACTA , cilt.412, ss.2296-2299, 2011 (SCI-Expanded) identifier identifier identifier

156. Cytokeratins in hepatitis

YILMAZ Y.
CLINICA CHIMICA ACTA , cilt.412, ss.2031-2036, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

157. Plasma Fibrinogen-Like Protein 2 Levels in Patients with Non-Alcoholic Fatty Liver Disease

Colak Y., Senates E., Ozturk O., YILMAZ Y., Coskunpinar E., Kahraman O. T., et al.
HEPATO-GASTROENTEROLOGY , cilt.58, sa.112, ss.2087-2090, 2011 (SCI-Expanded) identifier identifier identifier

158. Serum levels of soluble receptor for advanced glycation endproducts (sRAGE) are higher in ulcerative colitis and correlate with disease activity

Yilmaz Y., Yonal O., Eren F., Atug O., Hamzaoglu H. O.
Journal of Crohn's and Colitis , cilt.5, sa.5, ss.402-406, 2011 (SCI-Expanded) identifier identifier identifier

159. Association Between The Presence of Brown Adipose Tissue and Nonalcoholic Fatty Liver Disease in Adult Humans

Yilmaz Y., Ones T., Purnak T., Kurt R., Ozguven S., Atug O., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , cilt.38, 2011 (SCI-Expanded) identifier

160. A Glance at the methods for detection of apoptosis qualitatively and quantitatively

Ulukaya E., Açılan C., Arı F., Elif İlkay İ., Yılmaz Y.
A Glance at the methods for detection of apoptosis qualitatively and quantitatively , cilt.36, ss.261-269, 2011 (Hakemli Dergi) identifier identifier

161. Serum galectin-3 levels in patients with nonalcoholic fatty liver disease

YILMAZ Y., EREN F., Kurt R., Yonal O., Polat Z., Senates E., et al.
CLINICAL BIOCHEMISTRY , cilt.44, sa.12, ss.955-958, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

162. Association between the presence of brown adipose tissue and non-alcoholic fatty liver disease in adult humans.

Yilmaz Y., Ones T., Purnak T., Ozguven S., Kurt R., Atug O., et al.
Alimentary pharmacology & therapeutics , cilt.34, sa.3, ss.318-23, 2011 (SCI-Expanded) identifier identifier identifier

163. Serum Levels of Hepcidin in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease

Senates E., YILMAZ Y., Colak Y., Ozturk O., Altunoz M. E., Kurt R., et al.
METABOLIC SYNDROME AND RELATED DISORDERS , cilt.9, sa.4, ss.287-290, 2011 (SCI-Expanded) identifier identifier identifier

164. Apoptosis: why and how does it occur in biology?

ULUKAYA E., Acilan C., YILMAZ Y.
CELL BIOCHEMISTRY AND FUNCTION , cilt.29, sa.6, ss.468-480, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

165. Author's Reply; Noninvasive tests of fibrosis: To get the right answers, we need to ask the right questions

Yılmaz Y., Kurt R.
Hepatitis Monthly , cilt.11, sa.8, ss.668-670, 2011 (SCI-Expanded) identifier identifier

166. Author's Reply; Noninvasive Tests of Fibrosis: To Get the Right Answers, We Need to Ask the Right Questions

YILMAZ Y., Kurt R.
HEPATITIS MONTHLY , cilt.11, sa.8, ss.669-670, 2011 (SCI-Expanded) identifier identifier

167. Multimarker Strategies for Detecting NASH and NASH-Related Fibrosis: Promises and Caveats

YILMAZ Y., Kurt R., EREN F.
OBESITY SURGERY , cilt.21, sa.8, ss.1316-1317, 2011 (SCI-Expanded) identifier identifier identifier

168. Authors' Reply: Noninvasive liver fibrosis assessment; Why does the APRI not work for Hepatitis B?

YILMAZ Y., Yonal O., Kurt R.
HEPATITIS MONTHLY , cilt.11, sa.7, ss.557, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

169. Reply to Aydin et al: "To what extent is it right to measure serum vaspin, obestatin, and apelin-36 levels without a protease inhibitor in nonalcoholic fatty liver disease?"

Yılmaz Y., Eren F.
Metabolism: Clinical and Experimental , cilt.60, 2011 (SCI-Expanded) identifier

170. Circulating vaspin levels and epicardial adipose tissue thickness are associated with impaired coronary flow reserve in patients with nonalcoholic fatty liver disease

YILMAZ Y., Kurt R., Gurdal A., ÖZEN ALAHDAB Y., Yonal O., Senates E., et al.
ATHEROSCLEROSIS , cilt.217, sa.1, ss.125-129, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

171. Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease

Aktas B., YILMAZ Y., EREN F., Yonal O., Kurt R., Alandab Y., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.60, sa.4, ss.544-549, 2011 (SCI-Expanded) identifier identifier identifier

172. Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori

Bekar O., YILMAZ Y., Gulten M.
JOURNAL OF MEDICINAL FOOD , cilt.14, sa.4, ss.344-347, 2011 (SCI-Expanded) identifier identifier identifier

173. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease

YILMAZ Y., Yonal O., Kurt R., Bayrak M., Aktas B., Ozdogan O.
HEPATITIS MONTHLY , cilt.11, sa.2, ss.103-107, 2011 (SCI-Expanded) identifier identifier identifier

174. Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis

Yilmaz Y., Ulukaya E.
CURRENT MEDICINAL CHEMISTRY , cilt.18, sa.5, ss.725-732, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

175. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Eren F., Ozdogan O., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.46, sa.1, ss.91-97, 2011 (SCI-Expanded, Scopus) identifier identifier identifier

176. Serum progranulin as an independent marker of liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease

Yılmaz Y., Eren F., Yonal O., Polat Z., Bacha M., Kurt R., et al.
Disease Markers , cilt.31, ss.205-210, 2011 (SCI-Expanded) identifier identifier identifier

177. Protective effect of the vasopressin agonist terlipressin in a rat model of contrast-induced nephropathy.

Ari E., Yılmaz Y., Kedrah A. E., Alahdab Y., Cakalagaoglu F., Arikan H., et al.
American journal of nephrology , cilt.33, sa.3, ss.269-76, 2011 (SCI-Expanded) identifier identifier identifier

178. Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease

Yılmaz Y., Yonal O., Kurt R., Alahdab Y., Ozdogan O., Celikel Ç., et al.
ARCHIVES OF MEDICAL RESEARCH , cilt.42, sa.1, ss.38-43, 2011 (SCI-Expanded) identifier identifier identifier

179. Serum zinc-alpha(2)-glycoprotein concentrations in patients with non-alcoholic fatty liver disease

Yılmaz Y., Yonal O., Eren F., Kurt R., Celikel Ç., Ozdogan O., et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE , cilt.49, sa.1, ss.93-97, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

180. Caspase-cleaved fragments of cytokeratin 18 in patients with chronic hepatitis B

EREN F., YILMAZ Y., Kose S., Ozdemir F. T., Yonal O., Kurt R., et al.
CLINICA CHIMICA ACTA , cilt.411, ss.2029-2032, 2010 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

181. Liver Enzymes and Cardiovascular Outcomes a New Research Agenda

YILMAZ Y., Kuri R., Kalayci C.
HEPATOLOGY , cilt.52, sa.6, ss.2242, 2010 (SCI-Expanded) identifier identifier identifier

182. Liver function tests: Association with cardiovascular outcomes

Yılmaz Y.
World Journal of Hepatology , cilt.2, ss.143-145, 2010 (SCI-Expanded) identifier identifier

183. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease

Yılmaz Y., Yonal O., Kurt R., Oral A. Y., Eren F., Ozdogan O., et al.
Scandinavian Journal of Clinical and Laboratory Investigation , cilt.70, ss.541-546, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

184. Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis

YILMAZ Y., Yonal O., Kurt R., ARI F., YILMAZTEPE ORAL A., ÇELİKEL Ç., et al.
ANNALS OF CLINICAL BIOCHEMISTRY , cilt.47, ss.549-553, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

185. Apoptosis in nonalcoholic steatohepatitis with normal aminotransferase values: zooming in on cytokeratin 18 fragments

YILMAZ Y., Kurt R., Kalayci C.
BIOMARKERS IN MEDICINE , cilt.4, sa.5, ss.743-745, 2010 (SCI-Expanded) identifier identifier identifier

186. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease

Yılmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Çelikel Ç., et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION , cilt.40, sa.10, ss.887-892, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

187. Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis

YILMAZ Y., Alanhdab Y., Yonal O., Kurt R., Kedrah A. E., ÇELİKEL Ç., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.59, sa.9, ss.1327-1330, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

188. Microalbuminuria and nonalcoholic fatty liver disease

Yılmaz Y., Alahdab Y. O., Yonal O., Imeryuz N., Kalayci C.
Metabolism: Clinical and Experimental , cilt.59, 2010 (SCI-Expanded) identifier

189. Folic Acid and Vitamin B12 Supplementation Improves Coronary Flow Reserve in Elderly Subjects with Vitamin B12 Deficiency

Kurt R., YILMAZ Y., Ermis F., Besisik S. K., Polat N., Elitok A., et al.
ARCHIVES OF MEDICAL RESEARCH , cilt.41, sa.5, ss.369-372, 2010 (SCI-Expanded) identifier identifier identifier

190. Cigarette Smoking Is Not Associated with Specific Histological Features or Severity of Nonalcoholic Fatty Liver Disease

YILMAZ Y., Yonai O., Kurt R., Avsar E.
HEPATOLOGY , cilt.52, sa.1, ss.391, 2010 (SCI-Expanded) identifier identifier

191. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: Association with liver fibrosis

YILMAZ Y., Kurt R., Yonal O., Polat N., ÇELİKEL Ç., Gurdal A., et al.
ATHEROSCLEROSIS , cilt.211, sa.1, ss.182-186, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

192. The AGEs-RAGE axis and nonalcoholic steatohepatitis: the evidence mounts

Yilmaz Y.
JOURNAL OF GASTROENTEROLOGY , cilt.45, sa.7, ss.782-783, 2010 (SCI-Expanded) identifier identifier identifier

193. C-KIT Gene Polymorphism in Achalasia

Alahdab Y. O., EREN F., Gunduz F., Kedrah A. E., YILMAZ Y., Atug O., et al.
GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded) identifier

194. The Impact of Prophylactic Percutaneus Endoscopic Gastrostomy to Nutritional Status and Quality of Life in Locally Advanced Head and Neck Cancer Patients Receiving Chemoradiotherapy

Yonal O., Atasoy B. M., Demirel B., YILMAZ Y., Dane F., ABACIOGLU M. U., et al.
GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

195. Microalbuminuria in Nondiabetic Patients With Nonalcoholic Fatty Liver Disease: Association With Liver Fibrosis

YILMAZ Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel Ç., et al.
GASTROENTEROLOGY , cilt.138, sa.5, 2010 (SCI-Expanded) identifier

196. Molecular Signatures of Nonalcoholic Fatty Liver Disease: The Present and Future

YILMAZ Y., ULUKAYA E.
HEPATOLOGY , cilt.51, sa.5, ss.1866, 2010 (SCI-Expanded) identifier identifier identifier

197. Plasma prohepcidin levels in patients with chronic viral hepatitis: relationship with liver fibrosis

Olmez O. F., Gurel S., YILMAZ Y.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.22, sa.4, ss.461-465, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

198. M30 levels and nonalcoholic steatohepatitis in polycystic ovary syndrome

Yılmaz Y., Kurt R.
Journal Of Clinical Endocrinology , cilt.0, sa.0, 2010 (SCI-Expanded)

199. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetes mellitus patients

Gul O. O., Tuncel E., YILMAZ Y., ULUKAYA E., Gul C. B., Kiyici S., et al.
METABOLISM-CLINICAL AND EXPERIMENTAL , cilt.59, sa.1, ss.64-69, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

200. Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: Relationship with the severity of coronary artery disease

Senturk T., Aydinlar A., Yilmaz Y., Yilmaztepe Oral A., Ozdabakoglu O., Ulukaya E.
Coronary Artery Disease , cilt.20, ss.494-498, 2009 (SCI-Expanded) identifier identifier identifier

201. Systematic review: Caspase-cleaved fragments of cytokeratin 18 - The promises and challenges of a biomarker for chronic liver disease

Yılmaz Y.
Alimentary Pharmacology and Therapeutics , cilt.30, ss.1103-1109, 2009 (SCI-Expanded) identifier identifier identifier

202. Familial Mediterranean Fever coexisting with celiac disease: Is there a link with long-term colchicine treatment?

Yilmaz Y., Baran B., Seniz N. B., Dolar E.
Journal of Gastrointestinal and Liver Diseases , cilt.18, ss.119-120, 2009 (SCI-Expanded) identifier identifier identifier

203. Metformin, hepatitis C, and insulin resistance: Sufficient evidence?

Yılmaz Y., Yonal O., Imeryuz N.
Hepatology , cilt.50, ss.2054-2055, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

204. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: Association with insulin resistance

Yılmaz Y., Ulukaya E., Atuğ Ö., Dolar E.
European Journal of Gastroenterology and Hepatology , cilt.21, ss.1247-1251, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

205. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients

Arabul M., Gullulu M., Yilmaz Y., Eren M. A., Baran B., Gul C. B., et al.
Medical Science Monitor , cilt.15, 2009 (SCI-Expanded) identifier identifier identifier

206. Non-alcoholic fatty liver disease and microalbuminuria in non-diabetic patients: Role of insulin resistance

Yılmaz Y., Alahdab Y., Özdoğan O. C., Dolar E.
Internal Medicine Journal , cilt.39, ss.709-710, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

207. Human serum complement C3 and factor H in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.

Ari E., YILMAZ Y., Gul A., ÖZEN ALAHDAB Y., Kedrah A. E., Macunluoglu B., et al.
American journal of reproductive immunology (New York, N.Y. : 1989) , cilt.62, sa.4, ss.238-42, 2009 (SCI-Expanded) identifier identifier identifier

208. Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis.

YILMAZ Y., Kedrah A. E., Ozdogan O. C.
World journal of gastroenterology , cilt.15, sa.35, ss.4387-91, 2009 (SCI-Expanded) identifier identifier identifier

209. Biomarkers for noninvasive biochemical diagnosis of nonalcoholic steatohepatitis: Tools or decorations?

YILMAZ Y., Dolar E.
WORLD JOURNAL OF GASTROENTEROLOGY , cilt.15, sa.34, ss.4346-4347, 2009 (SCI-Expanded) identifier identifier identifier

210. "Defragmenting" the Noninvasive Diagnosis of Nonalcoholic Steatohepatitis: Hopes from Cytokeratin-18

Yilmaz Y.
HEPATOLOGY , cilt.50, sa.3, ss.990-991, 2009 (SCI-Expanded) identifier identifier identifier

211. Commentary on "Cytokeratin 18, a Marker of Cell Death, is Increased in Children With Suspected Nonalcoholic Fatty Liver Disease"

YILMAZ Y., Dolar E., ULUKAYA E.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION , cilt.49, sa.3, ss.371, 2009 (SCI-Expanded) identifier identifier identifier

212. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond

Yilmaz Y., Ulukaya E., Dolar E.
Hepatology , cilt.49, ss.1056-1057, 2009 (SCI-Expanded) identifier identifier identifier

213. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels

Yilmaz Y., Ulukaya E., Dolar E.
Hepatology , cilt.49, ss.697, 2009 (SCI-Expanded) identifier identifier identifier

214. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

YILMAZ Y., ULUKAYA E., Gul O. O., Arabul M., Gul C. B., ATUĞ Ö., et al.
CLINICAL BIOCHEMISTRY , cilt.42, sa.9, ss.802-807, 2009 (SCI-Expanded) identifier identifier identifier

215. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.
Medical Science Monitor , cilt.15, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

216. Pegylated interferon/ribavirin-induced sudden sensorineural hearing loss in a patient with chronic hepatitis C

ATUĞ Ö., Akin H., YILMAZ Y., Sari M., Tozun N.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES , cilt.18, sa.2, ss.256, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

217. Coronary artery anomalies in patients with syndrome X

Akgüllü Ç., Yilmaz Y., Yücel E., Kaderli A. A., Kumbay E., Ayndinlar A.
Anadolu Kardiyoloji Dergisi , cilt.9, ss.69, 2009 (SCI-Expanded) identifier identifier identifier

218. Serum Levels of Adipokines in Patients with Chronic HCV Infection: Relationship with Steatosis and Fibrosis

Tiftikci A., ATUĞ Ö., YILMAZ Y., EREN F., Ozdemir F. T., Yapali S., et al.
ARCHIVES OF MEDICAL RESEARCH , cilt.40, sa.4, ss.294-298, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

219. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: Relation to disease severity

Keskin M., Dolar E., Dirican M., Kiyici M., Yilmaz Y., Gurel S., et al.
Internal Medicine Journal , cilt.39, ss.243-248, 2009 (SCI-Expanded) identifier identifier identifier

220. Dipeptidyl peptidase IV inhibitors: Therapeutic potential in nonalcoholic fatty liver disease

YILMAZ Y., ATUĞ Ö., Yonal O., DUMAN D., Ozdogan O., Imeryuz N., et al.
MEDICAL SCIENCE MONITOR , cilt.15, sa.4, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

221. Liver Disease as a Risk Factor for Cognitive Decline and Dementia: an Under-Recognized Issue

YILMAZ Y., Ozdogan O.
HEPATOLOGY , cilt.49, sa.2, ss.698, 2009 (SCI-Expanded) identifier identifier identifier

222. Small arterial elasticity predicts the extent of coronary artery disease: Relationship with serum uric acid

Fazlioǧlu M., Şentürk T., Kumbay E., Kaderli A. A., Yilmaz Y., Özdemir B., et al.
Atherosclerosis , cilt.202, ss.200-204, 2009 (SCI-Expanded) identifier identifier identifier

223. Proteomic analysis of serum in patients with non-alcoholic steatohepatitis using matrix-assisted laser desorption ionization time-of-flight mass spectrometry

ULUKAYA E., YILMAZ Y., Moshkovskii S., Karpova M., Pyatnitskiy M., ATUĞ Ö., et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY , cilt.44, sa.12, ss.1471-1476, 2009 (SCI-Expanded) identifier identifier identifier

224. Acute arsenic self-poisoning for suicidal purpose in a dentist: A case report

Yilmaz Y., Armagan E., Olmez O., Esen M., Alkis N., Dolar E.
Human and Experimental Toxicology , cilt.28, ss.63-65, 2009 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

225. Concomitant colitis in a patient with Behcet's disease

Yilmaz Y., Dolar E.
Journal of Gastrointestinal and Liver Diseases , cilt.17, sa.4, ss.481-483, 2008 (SCI-Expanded) identifier identifier identifier

226. Predictive value of the modified early warning score in a turkish emergency department

Armagan E., Yilmaz Y., Olmez O. F., Simsek G., Gul C. B.
European Journal of Emergency Medicine , cilt.15, ss.338-340, 2008 (SCI-Expanded) identifier identifier identifier

227. A "biomarker biopsy" for the diagnosis of NASH: Promises from CK-18 fragments

Yilmaz Y., Ulukaya E., Dolar E.
Obesity Surgery , cilt.18, ss.1507-1508, 2008 (SCI-Expanded) identifier identifier identifier

228. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease

Arabul M., Gullulu M., Yilmaz Y., Akdag I., Kahvecioglu S., Ali Eren M., et al.
Clinical Biochemistry , cilt.41, ss.1055-1058, 2008 (SCI-Expanded) identifier identifier identifier

229. Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease

Akgullu C., Ozdemir B., Yilmaz Y., Kazazoglu A. R., Aydinlar A.
Acta Cardiologica , cilt.63, sa.4, ss.467-471, 2008 (SCI-Expanded) identifier identifier identifier

230. The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-γ2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease

Catalano M., Cortelazzo A., Santi R., Contino L., Demicheli M., Yilmaz Y., et al.
Clinical Biochemistry , cilt.41, ss.981-985, 2008 (SCI-Expanded) identifier identifier identifier

231. Helicobacter pylori: A role in schizophrenia?

Yilmaz Y., Gul C. B., Arabul M., Eren M. A.
Medical Science Monitor , cilt.14, 2008 (SCI-Expanded) identifier identifier identifier

232. Apical ballooning syndrome: A metabolic form of cardiomyopathy?

Yilmaz Y.
Medical Science Monitor , cilt.14, 2008 (SCI-Expanded) identifier identifier identifier

233. Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention?

Bulent Gul C., Gullulu M., Oral B., Aydinlar A., Oz O., Budak F., et al.
Clinical Biochemistry , cilt.41, ss.544-547, 2008 (SCI-Expanded) identifier identifier identifier

234. Acute myocardial infarction, ischemic cerebrovascular disease and variceal bleeding due to portal vein thrombosis in a patient with hereditary thrombophilia

Baran B., Yilmaz Y., Algin O., Keskin M., Kiyici M., Kocamaz G., et al.
Blood Coagulation and Fibrinolysis , cilt.19, ss.243-246, 2008 (SCI-Expanded) identifier identifier identifier

235. The -374T/A RAGE Polymorphism Protects Against Future Cardiac Events in Nondiabetic Patients with Coronary Artery Disease

Falcone C., Geroldi D., Buzzi M. P., Emanuele E., Yilmaz Y., Fontana J. M., et al.
Archives of Medical Research , cilt.39, ss.320-325, 2008 (SCI-Expanded) identifier identifier identifier

236. Psychopathology in the context of obesity: The adiponectin hypothesis

Yilmaz Y.
Medical Hypotheses , cilt.70, ss.902-903, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

237. Clinical value of the malnutrition-inflammation-atherosclerosis syndrome for long-term prediction of cardiovascular mortality in patients with end-stage renal disease: A 5-year prospective study

Akdag I., Yilmaz Y., Kahvecioglu S., Bolca N., Ercan I., Ersoy A., et al.
Nephron - Clinical Practice , cilt.108, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

238. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease

Catalano M., Cortelazzo A., Yilmaz Y., Perilli E., Carzaniga G., Emanuele E.
Clinica Chimica Acta , cilt.387, ss.109-112, 2008 (SCI-Expanded) identifier identifier identifier

239. Evaluation of leukocyte esterase and nitrite strip tests to detect spontaneous bacterial peritonitis in cirrhotic patients

Torun S., Dolar E., Yilmaz Y., Keskin M., Kiyici M., Sinirtas M., et al.
World Journal of Gastroenterology , cilt.13, ss.6027-6030, 2007 (SCI-Expanded) identifier identifier identifier

240. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus

Akkaya O., Kiyici M., Yilmaz Y., Ulukaya E., Yerci O.
World Journal of Gastroenterology , cilt.13, ss.5481-5485, 2007 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

241. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis

Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., et al.
World Journal of Gastroenterology , cilt.13, ss.837-844, 2007 (SCI-Expanded) identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 107

1. ANALYSIS OF THE EFFICACY OF A HIGHER DAILY ARAMCHOL DOSE ON FIBROSIS IMPROVEMENT IN THE ARMOR STUDY OPEN LABEL PART

Gorfine T., Ratziu V., YILMAZ Y., Friedman S. L., Hayardeny L., Kadosh S., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 12 Kasım 2021, (Tam Metin Bildiri)

2. Development and validation of Agile 4 and Agile 3+: Novel FibroScan based scores for the diagnosis of cirrhosis and advanced fibrosis in patients with non-alcoholic fatty liver disease

YILMAZ Y.
French Hepatology congress (AFEF) 29 Eylül 2021-02 Ekim 2021, Biarritz, Fransa, 07 Temmuz 2021, (Tam Metin Bildiri)

3. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge?

Lazarus J., Mark H., Palayew A., Patrizia C., Colombo M., Ekstedt M., et al.
International Liver Congress, ELECTR NETWORK, 23 - 26 Haziran 2021, cilt.75, (Özet Bildiri) identifier

4. The Impact of COVID-19 Pandemic on Patients with Chronic Liver Disease (CLD): Data from the Global Registry

YOUNOSSI Z. M., YILMAZ Y., El Kassas M., Duseja A. K., Saeed H., Gammal E., et al.
International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.655, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

5. Individual patient data meta-analysis of the diagnostic performance of single and sequentially combined non-invasive tests in detecting advanced fibrosis

YILMAZ Y.
International Liver Congress (EASL), Roma, İtalya, 23 Haziran 2021, cilt.75, ss.259-260, (Tam Metin Bildiri)

6. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease

YOUNOSSI Z. M., Harrison S. A., Newsome P. N., CHAN W. K., YILMAZ Y., Ledinghen V. d., et al.
International Liver Congress (EASL), Roma, İtalya, 23 - 26 Haziran 2021, cilt.75, ss.257, (Tam Metin Bildiri)

7. A GLOBAL SURVEY OF PHYSICIANS KNOWLEDGE ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.830, (Tam Metin Bildiri)

8. CLINICAL PRESENTATION OF LEAN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY

YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.771-772, (Tam Metin Bildiri)

9. CLINICAL PRESENTATION AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC VIRAL HEPATITIS: DATA FROM THE GLOBAL LIVER REGISTRY (TM)

YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 21 Mayıs 2021, cilt.160, ss.821-822, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

10. THE IMPACT OF CHRONIC HEPATITIS B ON PATIENT-REPORTED OUTCOMES FROM THE GLOBAL LIVER REGISTRY (TM)

YILMAZ Y., Yu M., Lam B. P., Ferret M. A. B., Papatheodoridis G., Chan W. K., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

11. SIGNIFICANT KNOWLEDGE GAP ABOUT NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IN REAL-WORLD PRACTICES: A GLOBAL SURVEY OF HEPATOLOGISTS, GASTROENTEROLOGISTS, ENDOCRINOLOGISTS AND PRIMARY CARE PHYSICIANS

Younossi Z. M., Takahashi H., Eguchi Y., YILMAZ Y., El Kassas M., Zheng M., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) identifier

12. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA OF NON-ALCOHOLIC FATTY LIVER DISEASE: LONGITUDINAL DATA FROM THE GLOBAL NASH REGISTRY (TM)

Younossi Z. M., YILMAZ Y., Yu M., Wong V. W., Castellanos Fernandez M., Isakov V. A., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) identifier

13. PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C: DATA FROM THE GLOBAL LIVER REGISTRY (TM)

Yu M., El Kassas M., Lam B. P., Esmat G., Femandez M. C., Ferret M. A. B., et al.
Liver Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), ELECTR NETWORK, 13 - 16 Kasım 2020, cilt.72, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

14. Comparison of clinical and histological characteristics of biopsyproven non-alcoholic fatty liver patients with and without type 2 diabetes mellitus: 10 years of experience from a single tertiary care center

YILMAZ Y.
APASL 2020 Bali - 29th Annual Conference Asian Pacific Association for the Study of the Liver, Balvi, Letonya, 4 - 08 Mart 2020, cilt.14, ss.1-470, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

15. THE IMPACT OF FATIGUE ON PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS WITH CHRONIC LIVER DISEASE (CLD): DATA FROM THE GLOBAL LIVER REGISTRY (GLR)

YILMAZ Y.
Digestive Disease Week, Amerika Birleşik Devletleri, 23 Ocak 2020, cilt.158, ss.1269, (Tam Metin Bildiri)

16. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.1063-1064, (Tam Metin Bildiri)

17. CAN ADVANCED FIBROSIS RELIABLY EXCLUDED BY SIMPLE NON-INVASIVE FIBROSIS SCORING SYSTEMS?: PERFORMANCE OF FIB-4 AND NFS IN A BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE SAMPLE

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.1053-1054, (Tam Metin Bildiri)

18. SEVERE IMPAIRMENT OF PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.359, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

19. CLINICAL AND PATIENT-REPORTED OUTCOMES DATA FOR PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) ACROSS THE WORLD: DATA FROM THE GLOBAL NASH REGISTRY

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, (Tam Metin Bildiri)

20. DIFFERENCES IN THE CLINICAL PROFILE OF THE MOST COMMON CAUSES OF CHRONIC LIVER DISEASE (CLD) ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY.

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.463-465, (Tam Metin Bildiri)

21. CLINICAL AND PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION SEEN IN REAL-WORLD PRACTICES ACROSS THE WORLD: DATA FROM THE GLOBAL LIVER REGISTRY

YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Amerika Birleşik Devletleri, 08 Kasım 2019, cilt.70, ss.577-578, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

22. USEFULNESS OF ENDOSCOPIC ULTRASONOGRAPHY ELASTOGRAPHY (EUS-E) TO MEASURE LIVER STIFFNESS

Duman D. G., Alahdab Y., Demirtas C. O., YILMAZ Y., GÜNDÜZ F.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) identifier

23. THE UTILITY OF NONINVASIVE SCORES IN ASSESSING THE ADVANCED HEPATIC FIBROSIS IN TYPE 2 DIABETIC PATIENTS WITH BIOPSY PROVEN NONALCOHOLIC FATTY LIVER DISEASE

Alkayyali T., Quatranji L., Kaya E., Bakir A., YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) identifier

24. ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY

Bilgin B. O., SÜNBÜL M., Kani H. T., Demirtas C. O., KEKLİKKIRAN Ç., YILMAZ Y.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, Amerika Birleşik Devletleri, 8 - 12 Kasım 2019, cilt.70, (Özet Bildiri) identifier

25. lLver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Sun D., Fun Zhou Y., Kani H. T., Chen Fei Z., Pei Wu Z., Hong Lei M., et al.
EASL 2019, Paris, Fransa, 14 Nisan 2019, (Özet Bildiri)

26. ILver stiffness measurement: An alternative practical predictor for early kidney dysfunction in patients with non-alcoholic fatty liver disease

Sun D. Q., Ye F., Haluk Tarik K., Zheng C., Zhu P., Ma H., et al.
International Liver Congress / 54th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Vienna, Avusturya, 10 - 14 Nisan 2019, cilt.70, (Özet Bildiri) identifier

27. Translating NAFLD AASLD data to local practice

YILMAZ Y.
AASLD TASL Regional Connect Meeting, İstanbul, Türkiye, 15 - 16 Mart 2019, (Özet Bildiri)

28. Nonalcoholic Fatty Liver Disease(NAFLD) and Alcoholic Fatty Lİver Disease(AFLD): The impact of Alcohol Comsumpt,on and Metabolic Syndrome on Mortality

Younossi Z., Stepanova M., Ong J., Yılmaz Y., Duseja A., Eguchi Y., et al.
THE AASLD LIVER MEETING, South-Carolina, Amerika Birleşik Devletleri, 9 - 13 Kasım 2018, (Özet Bildiri)

29. Noninvazif Fibrozis ve Yağlanma Ölçümü:Fibroscan/CAP

YILMAZ Y.
4. Azerbaycan-Türkiye Ortak Hepatoloji Kursu, Baku, Azerbaycan, 06 Ekim 2018, (Özet Bildiri)

30. Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcoholic Fatty Liver Disease (AFLD): The Impact of Alcohol Consumption and Metabolic Syndrome on Mortality

Younossi Z. M., Stepanova M., Ong J., YILMAZ Y., Duseja A. K., Eguchi Y., et al.
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, San-Francisco, Kostarika, 9 - 13 Kasım 2018, cilt.68, (Özet Bildiri) identifier

31. Non-alcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma listed for liver transplantation in United States: data from the Scientific Registry of Transplant Recipients

Younossi Z., Stepanova M., Ong J., Jacobson I., Bugianesi E., Duseja A., et al.
Joint International Congress of ILTS, ELITA and LICAGE, Lisbon, Portekiz, 23 - 26 Mayıs 2018, cilt.102, ss.304-305, (Özet Bildiri) identifier

32. Transient elastography with controlled attenuation parameterin the assessment of hepatic steatosis and significant liver fibrosisin patients with scleroderma

Yılmaz Y., Kani H. T., Şahinkaya Y., Mursaloğlu H. H., Aziziy M., İnanç G. N., et al.
27th Annual Conference of APASL, Dilli, Hindistan, 14 - 18 Mart 2018, cilt.12, ss.378, (Özet Bildiri)

33. Karaciğer fibrozisinin değerlendirilmesinde elastografinin rolü

YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)

34. Klinik pratikte transiyent elastografi kullanımı

YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)

35. Tanıdan tedaviye alkole bağlı olmayan yağlı karaciğer hastalığı

YILMAZ Y.
Baku 2018 Hepatoloji Sempozyumu, Baku, Azerbaycan, 21 Ocak 2018, (Özet Bildiri)

36. Preliminary evidence of an association between mtDNA D-loop polymorphisms and the clinicopathological features of nonalcoholic steatohepatitis

Hasturk B., Yılmaz Y., Eren F.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri) identifier

37. Nonalcoholic steatohepatitis: modulation of histological phenotype by the missense Thr174Met (rs4762) polymorphism of the angiotensinogen (AGT) gene

EREN F., Balcilar H., Yilmaz D., Toker T., YILMAZ Y., Hasturk B.
68th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Washington, Kiribati, 20 - 24 Ekim 2017, cilt.66, (Özet Bildiri) identifier

38. Mitochondrial DNA control region nucleotide variations in non-alcoholic steatohepatitis

Hasturk B., Yılmaz Y., Eren F.
European Biotechnology Congress, Dubrovnik, Hırvatistan, 25 - 27 Mayıs 2017, cilt.256, (Özet Bildiri) identifier

39. Prevalence of fatty liver in inflammatory bowel disease : a transient elastography study on the basis of a controlled attenuation parameter.

YILMAZ Y., KANİ H. T.
5th Annual Meeting of the Asian Organization for Crohn’s and Colitis, Seul, Güney Kore, 15 - 17 Haziran 2017, (Özet Bildiri)

40. Prevalence of Fatty Liver in IBD: ATransient Elastography Study on theBasis of a Controlled AttenuationParameter

Kani H. T., Demirtas I., Yılmaz Y.
The 5th Annual Meeting of Asian Organization for Crohn’s Colitis, Seoul, Güney Kore, 15 - 17 Haziran 2017, ss.235-236, (Özet Bildiri)

41. NAFLD: Yeni ne var?

YILMAZ Y.
11. Ulusal Hepatoloji Kongresi, Antalya, Türkiye, 17 - 21 Mayıs 2017, (Özet Bildiri)

42. Hepatit C Tedavilerinin İlaç Etkileşimleri

YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

43. Marmara Üniversitesi Tıp Fakültesi Harvoni Deneyimi

YILMAZ Y.
Sağlık Bilimleri Üniversitesi Gastroenteroloji Günleri, İstanbul, Türkiye, 28 - 29 Nisan 2017, (Özet Bildiri)

44. NASH'te yeni ne var?

YILMAZ Y.
14. Ulusal Hepatogastroenteroloji Kongresi, Antalya, Türkiye, 5 - 08 Nisan 2017, (Özet Bildiri)

45. Yüzyılın Epidemisi Alkol Dışı Karaciğer Yağlanması Hastalığı

YILMAZ Y.
33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Aralık 2016

46. COMPARİSİON OF DOPPLER ULTRASOUND AND TRANSİENT ELASTOGRAPHY FOR DİAGNOSİS OF SİGNİFİCANT FİBROSİS İN NONALCOHOLİC STEATOHEPATİT

ERGELEN R., YILMAZ Y., ASADOV R., CELİKEL Ç., AKIN H., BUGDAYCI O., et al.
ESGAR, 14 - 16 Aralık 2016, (Özet Bildiri)

47. Obezite ve yağlı karaciğer

YILMAZ Y.
7. Ulusal Obezite Kongresi, İstanbul, Türkiye, 8 - 11 Aralık 2016 Sürdürülebilir Kalkınma

48. Sülfasalazin kullanımı sonrası gelişen Dress sendromu Olgu sunumu

DURĞAY M., AYKUT U. E., ÖZEN ALAHDAB Y., YILMAZ Y., DEMİR O.
33. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)

49. Türk toplumunda alkolik olmayan yağlı karaciğer hastalığının genetik polimorfizm ile ilişkisi çok merkezli kontrollü çalışma

UYGUN A., öztürk k., DEMİRCİ H., öztuna a., EREN F., YILMAZ Y., et al.
33.Ulusal gastronetroloji haftası, Antalya, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)

50. İrritabl barsak sendromlu hastalarda yüksek laktoz intolerans sıklığı

hasanov r., ÖZEN ALAHDAB Y., EREN F., GÜNDÜZ F., YILMAZ Y., AYKUT U. E.
33.Ulusal gastroenetroloji haftası, Türkiye, 22 - 27 Kasım 2016, (Özet Bildiri)

51. Two atypical forms of Nonalcoholic fatty liver disease NAFLD without metabolic syndrome and Lean NAFLD

YILMAZ Y.
APASL Single Topic Conference, İstanbul, Türkiye, 22 - 24 Eylül 2016, (Tam Metin Bildiri)

52. Bactericidal permeability increasing protein has no effect on remission of ulcerative colitis

EREN F., eroğlu k., Banzragch M., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016

53. MT ND5 gene variants have both protective and risk factor for inflammatory bowel disease

Eren F., Safarova C., Gündüz F., Özen Alahdab Y., Kurt R., Yılmaz Y., et al.
The 4th Annual Meeting of Asian Organization for Crohn's & Colitis, Kyoto, Japonya, 7 - 09 Temmuz 2016, (Özet Bildiri)

54. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis

ERGELEN R., YILMAZ Y., ASADOV R., ÇELİKEL Ç., AKIN H., BUGDAYCI O., et al.
European Society of Gastrointestinal and Abdominal Radiology, 14 - 17 Haziran 2016

55. Yağlı Karaciğerde Yeni İlaç Tedavileri

YILMAZ Y.
Klinik Gastroenteroloji Toplantısı-5, İstanbul, Türkiye, 02 Haziran 2016

56. Kronik Viral Hepatitlerde Non İnvazif Yöntemle Fibrozis Belirleme Algoritmleri

YILMAZ Y.
Hepatit B Enfeksiyonu Akademisi, Çanakkale, Türkiye, 28 Mayıs 2016

57. Controlled attenuation parameter and liver stiffness measurements by fibroscan for the detection of non alcoholic fatty liver disease in patients with type 2 diabetes results from a pilot study

DURĞAY M., DEYNELİ O., YILMAZ Y.
EASL monothematic conference 2016, Riga, Letonya, 12 - 14 Mayıs 2016, (Özet Bildiri) Sürdürülebilir Kalkınma

58. Karaciğer Hasarının Değerlendirilmesi Non İnvazif Testlere Algoritmik Yaklaşım

YILMAZ Y.
XIII. Ulusal Viral Hepatit Kongresi, Antalya, Türkiye, 17 - 20 Mart 2016

59. Alkol Dışı Yağlı Karaciğer Hastalığında Yeni Ne Var

YILMAZ Y.
TKAD Mezuniyet Sonrası Eğitim Sempozyumu: Karaciğerde Çok Yenilik Var:AASLD 2015’den Süzülenler, İstanbul, Türkiye, 13 Ocak 2016

60. Karaciğer Fibrozisinde Yeni Non İnvaziv Yöntem ELF Test

DURUSOY S. S., ÖZDEMİR F. T., ÖZDOĞAN O. C., RAHMİ A., YILMAZ Y., YEĞİN E. G., et al.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

61. Does Helicobacter pylori Infection Influences the Complication rate After Sleeve Gastrectomy From an Endemic Region

AKYÜZ Ü., ALTUN H., BURÇİN B., YILMAZ Y., DERYA U.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

62. Ülseratif Kolitin ÜK Hastalık Aktivitesi Bakterisidal Permeabilite Arttırıcı Protein BPI Düzeyi ile İlişkilidir

EREN F., EROĞLU K., MUNKHTSETSEG B., ALAHDAB Y. Ö., KURT R., YILMAZ Y., et al.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015

63. NASH Pategenez ve Tedavisinde Yeni Bir Şey Var Mı

YILMAZ Y.
32.Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 25 - 29 Kasım 2015

64. Diyabetik Hastalarda Nonalkolik Yağlı Karaciğer Hastalığının ve Fibrozisin Fibroscan Aracılı CAP ve Karaciğer Sertlik Ölçümü ile Prospektif Taranması Ön Bulgularımız

DURĞAY M., DEYNELİ O., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015 Sürdürülebilir Kalkınma

65. Ülseratif kolitin hastalık aktivitesi bakterisidal permeabilite arttırıcı protein BPI düzeyi ile ilişkilidir

EREN F., eroğlu k., banzragch m., GÜNDÜZ F., ÖZEN ALAHDAB Y., KURT R., et al.
32. Ulusal Gastroenetroloji Haftası, Türkiye, 25 - 29 Kasım 2015

66. NAFLD in absence of Metabolic Syndrome

YILMAZ Y.
FRONTIERS IN HEPATOLOGY Non-alcoholic Fatty Liver Disease & the Metabolic Syndrome – Key questions on disease consequences and treatment –, Londrina, Brezilya, 24 Kasım 2015, (Tam Metin Bildiri)

67. Latent tüberküloz tanısında interferon gamma salınım testi ile tüberkülin deri testinin karşılaştırılması

ÖZEN ALAHDAB Y., Kedrah A. E., GÜNDÜZ F., YÖNAL O., YILMAZ Y., ALAHDAB H., et al.
BUHASDER 6.Tepecik Enfeksiyon Günleri Sempozyumu, Muğla, Türkiye, 4 - 08 Kasım 2015 Sürdürülebilir Kalkınma

68. Nonalkolik Yağlı Karaciğerli Hastalarda İleri Evre Fibrozisin Saptanmasında Noninvazif Yeni Bir Yöntem Olan Fibrometer VCTE nin Tanısal Performansı

DİNÇSES E., YILMAZ Y.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.21

69. Aktif Kahverengi Yağ Dokusu Varlığı Yağlı Karaciğer Hastalığı Gelişimini Önlüyor Olabilir

Salih Ö., Tunç Ö., YILMAZ Y., TUROĞLU H. T., İMERYÜZ N.
32. Ulusal Gastroenteroloji Haftası, Türkiye, 25 - 29 Kasım 2015, cilt.26, ss.43-44

70. Non alcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with non alcoholic fatty liver disease

SÜNBÜL M., KIVRAK T., DURMUŞ E., AKIN H., AYDIN Y., ERGELEN R., et al.
31. TURKISH CARDIOLOGY CONGRESS WITH INTERNATIONAL PARTICIPATION, 22 - 25 Ekim 2015

71. Can FibroMeter VCTE (TM) be useful for detecting hepatic fibrosis in patients with non-alcoholic fatty liver disease?

Dincses E., YILMAZ Y.
66th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD), San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, (Özet Bildiri) identifier

72. Can FibroMeter VCTE be useful for detecting hepatic fibrosis in patients with non alcoholic fatty liver disease

DİNÇSES E., YILMAZ Y.
The AASLD Liver Meeting 2015, San-Francisco, Kostarika, 13 - 17 Kasım 2015, cilt.62, ss.1270 identifier

73. Yeni Antikoagülanlar İşlem öncesi ve sonrası yaklaşım

YILMAZ Y.
3.Gastrointestinal Endoskopi Günleri, İstanbul, Türkiye, 8 - 09 Mayıs 2015

74. Characterization of Lean Patients With Nonalcoholic Fatty Liver Disease Potential Role of High Hemoglobin Levels

AKYÜZ Ü., YEŞİL A., YILMAZ Y.
46th Annual Digestive Disease Week (DDW), Washington, Kiribati, 16 - 19 Mayıs 2015, cilt.148, ss.1058 identifier identifier identifier

75. Noninvasive tests in the diagnosis of Non Alcoholic Fatty Liver Disease

YILMAZ Y.
The 24th Conference of the Asian Pacific Association for the Study of Liver (APASL), İstanbul, Türkiye, 12 - 15 Mart 2015

76. Yağlı Karaciğer Non alkolik Steatohepatit ve Alkolik Steatohepatit

YILMAZ Y.
Uludağ İç Hastalıkları Kış Kongresi, Bursa, Türkiye, 08 Mart 2015

77. Hepatoselüler Karsinoma Karsinogenezde endokrin metabolik mekanizmalar

YILMAZ Y.
13. Hepatoloji Sempozyumu, Ankara, Türkiye, 17 Ocak 2015

78. Barsak karaciğeri nasıl etkiler

YILMAZ Y.
31. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 24 - 28 Kasım 2014

79. Otoimmün hepatit ilaç hepatotoksisitesi yağlı karaciğer ve hepatitte yaklaşım ilaç seçimi ve izlem

YILMAZ Y.
A’dan Z’ye Psöriazis Toplantısı, İstanbul, Türkiye, 08 Kasım 2014 Sürdürülebilir Kalkınma

80. Klinik Araştırma Planlaması

YILMAZ Y.
11. Ulusal HEBİPA Kongresi, Kıbrıs (Kktc), 24 - 28 Eylül 2014

81. Alkol Dışı Yağlı Karaciğer Hastalığı

YILMAZ Y.
1. TÜRKİYE-AZERBAYCAN ORTAK HEPATOLOJİ KURSU, İstanbul, Türkiye, 18 - 19 Eylül 2014

82. Biodegradable Stentler

YILMAZ Y.
Türk Gastroenteroloji Derneği İstanbul Şubesi Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 25 Haziran 2014

83. Fibrokistik Karaciğer Hastalıkları

YILMAZ Y.
Türk Karaciğer Araştırmaları Derneği Mezuniyet Sonrası Eğitim Toplantısı, İstanbul, Türkiye, 13 Haziran 2014

84. KC biyopsi Fibroscan uygulamaları

AYGÜN C., YILMAZ Y.
5. Hepatoloji Okulu, Kocaeli, Türkiye, 30 Mayıs - 01 Haziran 2014

85. Karaciğer Transplantasyonlu Hastalarda Metabolik Komplikasyonlar ve Sorunların Yönetimi

YILMAZ Y.
Organ Nakilleri Bilinçlendirme ve Geliştirme DerneğiKaraciğer Nakli Mezuniyet Sonrası Eğitim Kursu 1, İstanbul, Türkiye, 24 Mayıs 2014

86. Alkol Dışı Yağlı Karaciğer Hastalıkları

YILMAZ Y.
İSTAHED Kongresi Viral Hepatitler ve Diğer Hepatobilier hastalıklarda Klinik Yaklaşım Kursu, Antalya, Türkiye, 10 Mayıs 2014

87. Nonalkolik yağlı karaciğer Nonalkolik steatohepatit

YILMAZ Y.
Türk Karaciğer Vakfı Mezuniyet Sonrası Eğitim Toplantıları, İstanbul, Türkiye, 29 Mart 2014

88. Erişkinde Yağlı Karaciğer Hastalığı ve Yönetimi Yenilik var mı

YILMAZ Y.
Karaciğer Hastalıkları ve Transplantasyonu Güncelleme Toplantısı, İstanbul, Türkiye, 01 Mart 2014

89. Are patients with biopsy proven non alcoholic fatty liver disease at increased risk of asthma Results from a Turkish cross sectional study

TAŞLI B., YILMAZ Y.
The Asian Pacific Society of Respirology 19th Congress, Balvi, Letonya, 13 - 16 Kasım 2014, cilt.19, ss.173-203 identifier

90. Fibroscan aracılı CAP kronik karaciğer hastalıklarında yağlanmanın şiddetini hastalık etyolojisinden ve fibrozisten bağımsız olarak doğru tahmin eder

YILMAZ Y., YEŞİL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.
30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013

91. CAP yöntemli Fibroscan ile karaciğer yağlanmasının kantitatif değerlendirilmesi Karaciğer biyopsisi ile karşılaştırmalı prospektif çalışma

YILMAZ Y., YESIL A., GERİN F., ERGELEN R., AKIN H., ÇELİKEL Ç., et al.
30. Ulusal Gastroenteroloji Haftası, Türkiye, 11 - 15 Ekim 2013

92. Evaluation of gallbladder kinetics in patients with nonalcoholic fatty liver disease

Colak Y., Bozbey G., Senates E., Doganay L., Coskunpinar E., Ozturk O., et al.
64th Annual Meeting and Postgraduate Course of the American-Association-for-the-Study-of-Liver-Diseases, Washington, Kiribati, 1 - 05 Kasım 2013, cilt.58, (Özet Bildiri) identifier

93. NAFLD da Metformin Hiç Vermeyelim mi

YILMAZ Y.
10.Ulusal Hepato Gastroenteroloji Kongresi, Magosa, Kıbrıs (Kktc), 25 - 29 Eylül 2013

94. Mikrobiyota ve Nonalkolik Yağlı Karaciğer Hastalığı

YILMAZ Y.
30. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 11 - 15 Eylül 2013

95. HEPATIC EXPRESSION AND SERUM LEVELS OF SYNDECAN 1 (CD138) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Eren F., Colak Y., Senates E., Celikel Ç., Imeryuz N.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri) identifier

96. HYPOTHYROIDISM IS NOT ASSOCIATED WITH SPECIFIC HISTOLOGICAL FEATURES OR SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Ayyildiz T., Colak Y., Senates E., Arabul M., Unsal B., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri) identifier identifier

97. GALLSTONE DISEASE IS NOT ASSOCIATED WITH LIVER FIBROSIS AND NONALCOHOLIC STEATOHEPATITIS IN NONALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Ayyildiz T., Akin H., Colak Y., Ozturk O., Senates E., et al.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri) identifier identifier

98. A BIOMARKER PANEL WITH HIGH SENSITIVITY AND SPECIFICITY FOR NONALCOHOLIC STEATOHEPATITIS IDENTIFIED BY SUPPORT VECTOR MACHINE

Yilmaz Y., Eren F.
International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Hollanda, 24 - 28 Nisan 2013, cilt.58, (Özet Bildiri) identifier

99. Metabolik Sendrom ve NAYK PAtogenezde Yenilikler

YILMAZ Y.
11. Hepatoloji Sempozyumu, Ankara, Türkiye, 18 - 19 Ocak 2013

100. NAFLD patogenezinde yeni ne var Steatoz koruyucu bir mekanizma mıdır

YILMAZ Y.
29. Ulusal Gastroenteroloji Haftası, Antalya, Türkiye, 20 - 25 Kasım 2012

101. NASH Tedavisinde Yenilikler

YILMAZ Y.
9. Ulusal HepatoGastroenteroloji Kongresi, Magosa, Kıbrıs (Kktc), 26 - 30 Eylül 2012

102. Non viral Hepatoselüler Kanser Etyolojisi NAFLD Alkol ve Diğer Faktörler

YILMAZ Y.
4. Hepatoloji Okulu, Muğla, Türkiye, 25 - 26 Mayıs 2012 Sürdürülebilir Kalkınma

103. Patogenezde VAT mı önemli SAT mı Günlük yaşamda fruktoz sanıldığı kadar suçlu mu

YILMAZ Y.
NAFLD Sempozyumu, Ankara, Türkiye, 24 Mart 2012

104. Association of MDRI Gene and Helicobacter pylori in the Development of Gastric Cancer and Gastritis

Eren F., Imeryuz N., Bas E., Ozkan N., Ozdemir F. T., Yilmaz Y., et al.
Conference on Digestive Disease Week 2011, Illinois, Amerika Birleşik Devletleri, 7 - 10 Mayıs 2011, cilt.140, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

105. CIRCULATING LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR A (VEGF) AND ITS SOLUBLE RECEPTOR SVEGFR-1 IN PATIENTS WITH BIOPSY-PROVEN NONALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Alahdab Y. O., Kurt R., Yonal O., Eren F., Kalayci C., et al.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, cilt.54, (Özet Bildiri) identifier

106. SERUM LEVELS OF OSTEOPROTEGERIN IN THE SPECTRUM OF NONALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Yonal O., Kurt R., Eren F., Imeryuz N., Kalayci C., et al.
46th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Berlin, Almanya, 30 Mart - 03 Nisan 2011, cilt.54, (Özet Bildiri) identifier

107. PLASMA LEVELS OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (SRAGE) IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE

Yilmaz Y., Ulukaya E., Gul O. O., Arabul M., Gul C. B., Atug O., et al.
44th Annual Meeting of the European-Association-for-the-Study-of-the-Liver, Copenhagen, Danimarka, 22 - 26 Nisan 2009, cilt.50, (Özet Bildiri) identifier identifier
Kitaplar 8

1. Covid-19 ve Karaciğer Yağlanması İlişkisi Nasıl Gelişmektedir?

Demirtaş C. Ö., YILMAZ Y.
Türkiye Klinikleri Gastroenteroloji ve Covid-19, Ahmet Uygun, Editör, Türkiye Klinikleri, Ankara, ss.39-44, 2021 Sürdürülebilir Kalkınma

2. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue

Kaya E., Yılmaz Y.
Obesity and Diabetes, Joel Faintuch,Salomão Faintuc, Editör, Springer-Verlag , Zürich, ss.1-987, 2020 Sürdürülebilir Kalkınma

3. Alkol Dışı Yağlı Karaciğer Hastalığı

KEFELİ A., YILMAZ Y.
Hepatobiliyer Sistem ve Pankreas Hastalıkları, Kefeli, Ayşe, Editör, Akademisyen Yayınevi, Ankara, ss.193-209, 2020

4. Non-alcoholic Fatty Liver Disease: A Global Public Health Issue

KAYA E., YILMAZ Y.
Obesity and Diabetes, Faintuch, Joel, Faintuch, Salomão, Editör, Springer, ss.321-333, 2020 Sürdürülebilir Kalkınma

5. Türkiye’de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi

Kaya E., Yılmaz Y.
Türkiye Klinikleri Gastroenterohepatoloji-Özel Konular: Nonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editör, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, ss.1-7, 2019 Creative Commons License Sürdürülebilir Kalkınma

6. Türkiye’de ve Dünyada Nonalkolik Yağlı Karaciğer Hastalığı Epidemiyolojisi

Kaya E., YILMAZ Y.
Türkiye Klinikleri Gastroenterohepatoloji-Özel KonularNonalkolik Yağlı Karaciğer Hastalığı, Abdullah Sonsuz, Editör, Türkiye Klinikleri (Ortadoğu Reklam Tanıtım Yayıncılık), Ankara, ss.1-7, 2019

7. Is NAFLD different in absence of metabolic syndrome?

Yılmaz Y.
Clinical Dilemmas in Non Alcoholic Fatty Liver Disease, Roger Williams,Simon D. Taylor-Robinson, Editör, Wiley-VCH Verlag Weinheim GmbH , London, ss.50-57, 2016

8. Obesity-Associated Nonalcoholic Fatty Liver Disease

YILMAZ Y., YOUNOSSI Z. M.
OBESITY A Multidisciplinary Approach, Joel J. Heidelbaugh, Editör, ELSEVIER, Philadelphia, ss.93-107, 2015 Sürdürülebilir Kalkınma
Metrikler

Yayın

364

Yayın (WoS)

264

Yayın (Scopus)

233

Atıf (WoS)

6062

H-İndeks (WoS)

34

Atıf (Scopus)

6788

H-İndeks (Scopus)

41

Atıf (Scholar)

1153

H-İndeks (Scholar)

19

Atıf (TrDizin)

6

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

15

Proje

20

Tez Danışmanlığı

12

Açık Erişim

24
BM Sürdürülebilir Kalkınma Amaçları